NO20130265A1 - Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser - Google Patents

Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser Download PDF

Info

Publication number
NO20130265A1
NO20130265A1 NO20130265A NO20130265A NO20130265A1 NO 20130265 A1 NO20130265 A1 NO 20130265A1 NO 20130265 A NO20130265 A NO 20130265A NO 20130265 A NO20130265 A NO 20130265A NO 20130265 A1 NO20130265 A1 NO 20130265A1
Authority
NO
Norway
Prior art keywords
activated
seq
pharmaceutical preparation
antibody against
insulin receptor
Prior art date
Application number
NO20130265A
Other languages
English (en)
Norwegian (no)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20130265(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of NO20130265A1 publication Critical patent/NO20130265A1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20130265A 2010-07-21 2013-02-18 Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser NO20130265A1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
PCT/IB2011/002177 WO2012010966A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Publications (1)

Publication Number Publication Date
NO20130265A1 true NO20130265A1 (no) 2013-04-18

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20130265A NO20130265A1 (no) 2010-07-21 2013-02-18 Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser

Country Status (30)

Country Link
US (1) US8617555B2 (cg-RX-API-DMAC7.html)
EP (2) EP2595658A2 (cg-RX-API-DMAC7.html)
JP (2) JP2013533268A (cg-RX-API-DMAC7.html)
KR (2) KR20180127515A (cg-RX-API-DMAC7.html)
CN (1) CN103118707A (cg-RX-API-DMAC7.html)
AR (1) AR082312A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011281240B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013001299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805961A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000200A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2013124A3 (cg-RX-API-DMAC7.html)
DE (1) DE112011102396T5 (cg-RX-API-DMAC7.html)
DK (1) DK201370089A (cg-RX-API-DMAC7.html)
EA (1) EA029847B1 (cg-RX-API-DMAC7.html)
EE (1) EE05761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2445846R1 (cg-RX-API-DMAC7.html)
FI (1) FI20135152L (cg-RX-API-DMAC7.html)
FR (1) FR2962913A1 (cg-RX-API-DMAC7.html)
GB (2) GB2552405B (cg-RX-API-DMAC7.html)
IT (1) ITTO20110627A1 (cg-RX-API-DMAC7.html)
LT (1) LT5980B (cg-RX-API-DMAC7.html)
MX (1) MX2013000804A (cg-RX-API-DMAC7.html)
MY (1) MY160979A (cg-RX-API-DMAC7.html)
NO (1) NO20130265A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ606964A (cg-RX-API-DMAC7.html)
PE (1) PE20130815A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500140A1 (cg-RX-API-DMAC7.html)
SE (1) SE1350212A1 (cg-RX-API-DMAC7.html)
SG (1) SG187578A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012010966A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) * 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria

Also Published As

Publication number Publication date
KR20180127515A (ko) 2018-11-28
EA201300124A1 (ru) 2013-12-30
LT5980B (lt) 2013-12-27
SG187578A1 (en) 2013-03-28
WO2012010966A2 (en) 2012-01-26
CZ2013124A3 (cs) 2013-06-12
PH12013500140A1 (en) 2013-03-11
US20130064824A1 (en) 2013-03-14
KR20130103486A (ko) 2013-09-23
GB2496799A (en) 2013-05-22
MX2013000804A (es) 2013-10-28
JP2013533268A (ja) 2013-08-22
ITTO20110627A1 (it) 2012-01-22
AR082312A1 (es) 2012-11-28
DE112011102396T5 (de) 2013-05-02
GB201707872D0 (en) 2017-06-28
FR2962913A1 (fr) 2012-01-27
FI20135152A7 (fi) 2013-02-21
EA029847B1 (ru) 2018-05-31
DK201370089A (en) 2013-02-19
CL2013000200A1 (es) 2015-01-23
EE05761B1 (et) 2016-03-15
LT2013018A (lt) 2013-10-25
AU2011281240A1 (en) 2013-03-07
US8617555B2 (en) 2013-12-31
GB2552405A (en) 2018-01-24
JP2016222684A (ja) 2016-12-28
ES2445846R1 (es) 2015-01-02
CA2805961A1 (en) 2012-01-26
GB2552405B (en) 2018-05-30
SE1350212A1 (sv) 2013-04-22
GB201302924D0 (en) 2013-04-03
ES2445846A2 (es) 2014-03-05
AU2011281240B2 (en) 2016-07-07
EP3693018A1 (en) 2020-08-12
CN103118707A (zh) 2013-05-22
PE20130815A1 (es) 2013-07-18
BR112013001299A2 (pt) 2017-11-21
WO2012010966A3 (en) 2012-03-29
NZ606964A (en) 2015-08-28
EE201300007A (et) 2013-08-15
EP2595658A2 (en) 2013-05-29
GB2496799B (en) 2017-11-22
FI20135152L (fi) 2013-02-21
MY160979A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
NO20130265A1 (no) Et farmasoytisk kombinasjonspreparat og fremgangsmater for behandling av diabetes og metabolske forstyrrelser
AU2011278039B2 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
FR2962652A1 (fr) Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
IL224336A (en) Combined Medication to Treat Vertigo, Kintosis and Vascular Dystonia Vascular
EP2596019A2 (en) A method of treating attention deficit hyperactivity disorder
MX2013001450A (es) Composicion farmaceutica y metodo para inhibir la produccion o amplificar la eliminacion de la proteina p24.
MX2013000543A (es) Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
AU2002242273B2 (en) Compositions of multimeric profilin for diagnosis and treatment of allergies
RU2531048C2 (ru) Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2565401C2 (ru) Способ лечения сахарного диабета и комбинированное лекарственное средство
RU2526153C2 (ru) Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
RU2523451C2 (ru) Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности
RU2525155C2 (ru) Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности
RU2543332C2 (ru) Лекарственное средство для коррекции эндотелиальной дисфункции
RU2523557C2 (ru) Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии
RU2542414C2 (ru) Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2525156C2 (ru) Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
RU2441023C1 (ru) Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2651005C2 (ru) Способ повышения фармакологической активности активированной-потенцированной формы антител к простатоспецифическому антигену и фармацевтическая композиция
RU2531049C2 (ru) Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application